Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Efficacy and Safety of Rapid-Acting Insulin Analogs in Special Populations with Type 1 Diabetes or Gestational Diabetes: Systematic Review and Meta-Analysis

Research output: Contribution to journalReviewResearchpeer-review

  1. A Response to "The Relationship Between Sleep and Quality of Life in Type 1 Diabetes Patients"

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Glycaemic variability and hypoglycaemia are associated with C-peptide levels in insulin-treated type 2 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Psychosocial factors and HbA1c in people with insulin-pump treated type 1 diabetes: Protocol for an ongoing systematic literature review

    Research output: Contribution to conferenceConference abstract for conferenceResearchpeer-review

  3. Glucose Sensor Accuracy After Subcutaneous Glucagon Injections Near to Sensor Site

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Dual-hormone artificial pancreas in person with type 1 diabetes

    Research output: Contribution to conferenceConference abstract for conferenceResearchpeer-review

View graph of relations

INTRODUCTION: To assess the efficacy and safety of three available rapid-acting insulin analogs (insulins lispro, aspart and glulisine, respectively) in pregnant women, children/adolescents and people using continuous subcutaneous insulin infusion (CSII) with type 1 diabetes.

METHODS: PubMed, EMBASE and Cochrane Reviews were searched electronically, and their bibliographies examined to identify suitable studies for review and inclusion in a meta-analysis. Eligible studies were randomized controlled trials that reported data on relevant clinical outcomes. A different reviewer abstracted data for each of the three subpopulations, and one reviewer abstracted data for all three. Any differences were resolved by consensus or by consulting a fourth reviewer.

RESULTS: In people on CSII, rapid-acting insulin analogs lowered postprandial plasma glucose post-breakfast to a greater extent than did regular human insulin (RHI) (mean difference: - 1.63 mmol/L [95% confidence interval - 1.71; - 1.54]), with a comparable risk of hypoglycemia and a trend for lower glycated hemoglobin. In the pediatric population, glycemic control was similar with rapid-acting insulin analogs and RHI, with no safety concerns. Meta-analysis indicated severe hypoglycemic events were comparable for rapid-acting insulin analogs versus RHI (risk difference: 0.00 [95% confidence interval - 0.01; 0.01]). In the pregnancy group, insulin lispro and insulin aspart were safe and effective for both mother and fetus, with glycemic control being at least as good as with RHI. There were no data on insulin glulisine during pregnancy.

CONCLUSION: Rapid-acting insulin analogs appear generally safe and effective in these special populations; however, additional trials would be helpful.

FUNDING: Novo Nordisk A/S.

Original languageEnglish
JournalDiabetes Therapy
Issue number3
Pages (from-to)891-917
Publication statusPublished - 1 Jun 2018

    Research areas

  • Journal Article, Review

ID: 53594776